CVRx is using this weekend’s Kansas City Heart Rhythm Society Symposium to spotlight Barostim, its device therapy for heart failure patients who do not respond

CVRx is using this weekend’s Kansas City Heart Rhythm Society Symposium to spotlight Barostim, its device therapy for heart failure patients who do not respond well to standard treatment. The company recently completed its sixth Barostim implant at Mount Sinai.